InventisBio Co., Limited (SHA:688382)

China flag China · Delayed Price · Currency is CNY
22.19
-0.76 (-3.31%)
At close: Apr 28, 2026
2.83%
Market Cap 12.83B
Revenue (ttm) 37.29M
Net Income (ttm) -316.87M
Shares Out 578.35M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,816,970
Average Volume 21,086,173
Open 22.97
Previous Close 22.95
Day's Range 22.00 - 23.55
52-Week Range 16.56 - 49.68
Beta 0.23
RSI 52.86
Earnings Date Apr 15, 2026

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II cli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 168
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688382
Full Company Profile

Financial Performance

In 2025, InventisBio's revenue was 37.29 million, a decrease of -77.91% compared to the previous year's 168.79 million. Losses were -316.87 million, 31.9% more than in 2024.

Financial Statements

News

There is no news available yet.